Clinical trial
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy…
NCT00179738 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00179738 |
|---|---|
| Title | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. |
| Official title | A Multicenter, Single-Arm, Open-Label, Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®) In Subjects With Androgen Independent Prostate Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | CC5013 |
| Enrollment | 40 |
| Start date | Apr 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 23, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: